New CFO for Mesoblast
Published By : 25 Aug 2014 | Published By : QYRESEARCH
Paul Hodgkinson has been welcomed by pharmaceutical company Mesoblast as their new Chief Financial Officer. Mr. Hodgkinson has proven himself by showing a high experience in all financial aspects of the pharmaceutical industry.
Between 2011 to 2014, Paul Hodgkinson was the Chief Financial Officer for Novartis ANZ Group, and had full financial responsibility in the divisions of Pharmaceuticals, Sandoz, Alcon, Consumer and Animal Health, and Vaccines and Diagnostics. Hodgkinson excels at working in finance, business development and licensing, strategic planning, procurement, and manufacturing and supply chain. He also held financial leadership positions in AstraZenica United Kingdom, as a Global Licensing Finance Director. He was later appointed as the Chief Financial Officer for AstraZeninca Australia from 2006 to 2011.
Jenni Pilcher will resign from her post as the current Chief Financial Officer for Mesoblast by the end of August, and will pursue a new role with an Australian biotechnology firm, Alchemia. She will begin work as a CFO with Alchemia in early September. Thomas Liquard, the Chief Executive Officer of Alchemia, stated that Jenni has an outstanding track record in the finance aspects of the biotech industry. He expects her executive maturity to be of great use to Alchemia during their current critical phase. The company is awaiting the results of their trial for HA-Irinotecan, a drug for metastatic colorectal cancer.
Mesoblast plans to consolidate its position as a world leader of biological products in regenerative medicine. Their product development focus lies in the four major areas of systemic diseases, orthopedic spinal diseases, genetic improvements in bone marrow transplants, and cardiac and vascular diseases.